Search All UT System Experts

The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives

Rehana Z. Hussain, Peter V. Sguigna, Annette Okai, Crystal Wright, Mariam Madinawala, Ann D. Bass, Gary R. Cutter, Navid Manouchehri, Olaf Stuve

Research output: Contribution to journal › Review article › peer-review

Fingerprint

Dive into the research topics of 'The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives'. Together they form a unique fingerprint.

Medicine & Life Sciences